featured
Efficacy and Safety of Tofacitinib, Peficitinib, Solcitinib, Baricitinib, Abrocitinib, and Deucravacitinib in Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of the European Academy of Dermatology and Venereology: JEADV
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis
J Eur Acad Dermatol Venereol 2022 May 24;[EPub Ahead of Print], L Zhang, L Guo, L Wang, X JiangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.